Peter Simon Macdonald
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Peter Simon Macdonald has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
L. Gao
The Victor Chang Cardiac Research Institute, Sydney, Australia
4 shared publicationsM. Hicks
The Victor Chang Cardiac Research Institute, Sydney, Australia
4 shared publicationsMark Hicks
St Vincent’s Hospital, Sydney
4 shared publicationsA M Keogh
Cardiology Department, St Vincent’s Hospital, Darlinghurst, Sydney, NSW, Australia
3 shared publicationsA. Doyle
The Victor Chang Cardiac Research Institute, Sydney, Australia
3 shared publicationsA. Jabbour
The Victor Chang Cardiac Research Institute, Sydney, Australia
3 shared publications
Latest Publications
- Open Access
- 22 January 2015
- Published by Elsevier in American Journal of Transplantation
- Vol. 15 (2) , 371-380
Normothermic Ex Vivo Perfusion Provides Superior Organ Preservation and Enables Viability Assessment of Hearts From DCD Donors
- 22 January 2015
- Published by Elsevier in American Journal of Transplantation
- Vol. 15 (2) , 371-380
Open AccessNormothermic Ex Vivo Perfusion Provides Superior Organ Preservation and Enables Viability Assessment of Hearts From DCD Donors
- 6 September 2014
- Published by Springer Nature in Current Transplantation Reports
- Vol. 1 (4) , 266-272
Size and Gender Matching in Heart Transplantation – Optimizing Donor Utilization in an Era of Changing Donor and Recipient Characteristics
- 6 September 2014
- Published by Springer Nature in Current Transplantation Reports
- Vol. 1 (4) , 266-272
Size and Gender Matching in Heart Transplantation – Optimizing Donor Utilization in an Era of Changing Donor and Recipient Characteristics
- 4 September 2014
- Published by Springer Nature in Current Transplantation Reports
- Vol. 1 (4) , 257-265
Primary Graft Dysfunction After Heart Transplantation
- 4 September 2014
- Published by Springer Nature in Current Transplantation Reports
- Vol. 1 (4) , 257-265
Primary Graft Dysfunction After Heart Transplantation
- Open Access
- 8 July 2014
- Published by Elsevier in American Journal of Transplantation
- Vol. 14 (8) , 1744-1752
Increasing the Tolerance of DCD Hearts to Warm Ischemia by Pharmacological Postconditioning
- 8 July 2014
- Published by Elsevier in American Journal of Transplantation
- Vol. 14 (8) , 1744-1752
Open AccessIncreasing the Tolerance of DCD Hearts to Warm Ischemia by Pharmacological Postconditioning
- 5 August 2013
- Published by AMPCo in Medical Journal of Australia
- Vol. 199 (3) , 147-148
The SNAPSHOT ACS study: getting the big picture on acute coronary syndrome
- 5 August 2013
- Published by AMPCo in Medical Journal of Australia
- Vol. 199 (3) , 147-148
The SNAPSHOT ACS study: getting the big picture on acute coronary syndrome
- Open Access
- 13 May 2013
- Published by Elsevier in American Journal of Transplantation
- Vol. 13 (7) , 1676-1687
Enhanced Preservation of Pig Cardiac Allografts by Combining Erythropoietin With Glyceryl Trinitrate and Zoniporide
- 13 May 2013
- Published by Elsevier in American Journal of Transplantation
- Vol. 13 (7) , 1676-1687
Open AccessEnhanced Preservation of Pig Cardiac Allografts by Combining Erythropoietin With Glyceryl Trinitrate and Zoniporide
- 25 September 2012
- Published by Springer Nature
- p. 237-249
Assessment, Monitoring, and Management of Brain-Dead Potential Organ Donors in Australia
- 25 September 2012
- Published by Springer Nature
- p. 237-249
Assessment, Monitoring, and Management of Brain-Dead Potential Organ Donors in Australia
- 1 May 2012
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 40 (5) , 1635-1644
A systematic review and meta-analysis of clinical trials of thyroid hormone administration to brain dead potential organ donors*
To review all published clinical studies of thyroid hormone administration to brain-dead potential organ donors. A search of PubMed using multiple search terms retrieved 401 publications including 35 original reports describing administration of thyroid hormone to brain-dead potential organ donors. Detailed review of the 35 original reports led to identification of two additional publications not retrieved in the original search. The 37 original publications reported findings from 16 separate case series or retrospective audits and seven randomized controlled trials, four of which were placebo-controlled. Meta-analysis was restricted to the four placebo-controlled randomized controlled trials. Whereas all case series and retrospective audits reported a beneficial effect of thyroid hormone administration, all seven randomized controlled trials reported no benefit of thyroid hormone administration either alone or in combination with other hormonal therapies. In four placebo-controlled trials including 209 donors, administration of thyroid hormone (n=108) compared with placebo (n=101) had no significant effect on donor cardiac index (pooled mean difference, 0.15 L/min/m²; 95% confidence interval -0.18 to 0.48). The major limitation of the case series and retrospective audits was the lack of consideration of uncontrolled variables that confound interpretation of the results. A limitation of the randomized controlled trials was that the proportion of donors who were hemodynamically unstable or marginal in other ways was too small to exclude a benefit of thyroid hormone in this subgroup. The findings of this systematic review do not support a role for routine administration of thyroid hormone in the brain-dead potential organ donor. Existing recommendations regarding the use of thyroid hormone in marginal donors are based on low-level evidence.
- 1 May 2012
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 40 (5) , 1635-1644
A systematic review and meta-analysis of clinical trials of thyroid hormone administration to brain dead potential organ donors*
To review all published clinical studies of thyroid hormone administration to brain-dead potential organ donors. A search of PubMed using multiple search terms retrieved 401 publications including 35 original reports describing administration of thyroid hormone to brain-dead potential organ donors. Detailed review of the 35 original reports led to identification of two additional publications not retrieved in the original search. The 37 original publications reported findings from 16 separate case series or retrospective audits and seven randomized controlled trials, four of which were placebo-controlled. Meta-analysis was restricted to the four placebo-controlled randomized controlled trials. Whereas all case series and retrospective audits reported a beneficial effect of thyroid hormone administration, all seven randomized controlled trials reported no benefit of thyroid hormone administration either alone or in combination with other hormonal therapies. In four placebo-controlled trials including 209 donors, administration of thyroid hormone (n=108) compared with placebo (n=101) had no significant effect on donor cardiac index (pooled mean difference, 0.15 L/min/m²; 95% confidence interval -0.18 to 0.48). The major limitation of the case series and retrospective audits was the lack of consideration of uncontrolled variables that confound interpretation of the results. A limitation of the randomized controlled trials was that the proportion of donors who were hemodynamically unstable or marginal in other ways was too small to exclude a benefit of thyroid hormone in this subgroup. The findings of this systematic review do not support a role for routine administration of thyroid hormone in the brain-dead potential organ donor. Existing recommendations regarding the use of thyroid hormone in marginal donors are based on low-level evidence.
- Open Access
- 1 August 2011
- Published by Hindawi Limited in Journal of Transplantation
- Vol. 2011, 1-9
Primary Graft Failure after Heart Transplantation
Primary graft failure (PGF) is a devastating complication that occurs in the immediate postoperative period following heart transplantation. It manifests as severe ventricular dysfunction of the donor graft and carries significant mortality and morbidity. In the last decade, advances in pharmacological treatment and mechanical circulatory support have improved the outlook for heart transplant recipients who develop this complication. Despite these advances in treatment, PGF is still the leading cause of death in the first 30 days after transplantation. In today's climate of significant organ shortages and growing waiting lists, transplant units worldwide have increasingly utilised “marginal donors” to try and bridge the gap between “supply and demand.” One of the costs of this strategy has been an increased incidence of PGF. As the threat of PGF increases, the challenges of predicting and preventing its occurrence, as well as the identification of more effective treatment modalities, are vital areas of active research and development.
- 1 August 2011
- Published by Hindawi Limited in Journal of Transplantation
- Vol. 2011, 1-9
Open AccessPrimary Graft Failure after Heart Transplantation
Primary graft failure (PGF) is a devastating complication that occurs in the immediate postoperative period following heart transplantation. It manifests as severe ventricular dysfunction of the donor graft and carries significant mortality and morbidity. In the last decade, advances in pharmacological treatment and mechanical circulatory support have improved the outlook for heart transplant recipients who develop this complication. Despite these advances in treatment, PGF is still the leading cause of death in the first 30 days after transplantation. In today's climate of significant organ shortages and growing waiting lists, transplant units worldwide have increasingly utilised “marginal donors” to try and bridge the gap between “supply and demand.” One of the costs of this strategy has been an increased incidence of PGF. As the threat of PGF increases, the challenges of predicting and preventing its occurrence, as well as the identification of more effective treatment modalities, are vital areas of active research and development.
- Open Access
- 2 March 2011
- Published by Springer Nature in Trials
- Vol. 12 (1) , 1-6
An intervention to promote physical activity and self-management in people with stable chronic heart failure The Home-Heart-Walk study: study protocol for a randomized controlled trial
Chronic heart failure (CHF) is a chronic debilitating condition with economic consequences, mostly because of frequent hospitalisations. Physical activity and adequate self-management capacity are important risk reduction strategies in the management of CHF. The Home-Heart-Walk is a self-monitoring intervention. This model of intervention has adapted the 6-minute walk test as a home-based activity that is self-administered and can be used for monitoring physical functional capacity in people with CHF. The aim of the Home-Heart-Walk program is to promote adherence to physical activity recommendations and improving self-management in people with CHF. A randomised controlled trial is being conducted in English speaking people with CHF in four hospitals in Sydney, Australia. Individuals diagnosed with CHF, in New York Heart Association Functional Class II or III, with a previous admission to hospital for CHF are eligible to participate. Based on a previous CHF study and a loss to follow-up of 10%, 166 participants are required to be able to detect a 12-point difference in the study primary endpoint (SF-36 physical function domain). All enrolled participant receive an information session with a cardiovascular nurse. This information session covers key self-management components of CHF: daily weight; diet (salt reduction); medication adherence; and physical activity. Participants are randomised to either intervention or control group through the study randomisation centre after baseline questionnaires and assessment are completed. For people in the intervention group, the research nurse also explains the weekly Home-Heart-Walk protocol. All participants receive monthly phone calls from a research coordinator for six months, and outcome measures are conducted at one, three and six months. The primary outcome of the trial is the physical functioning domain of quality of life, measured by the physical functioning subscale of the Medical Outcome Study Short Form -36. Secondary outcomes include physical functional capacity measured by the standard six minute walk test, self-management capacity, health related quality of life measured by Medical Outcome Study Short Form -36 and Minnesota Living With Heart Failure Questionnaire, self-efficacy and self-care behaviour. A self-monitoring intervention that can improve individual's exercise self-efficacy, self-management capacity could have potential significance in improving the management of people with chronic heart failure in community settings. Australian New Zealand Clinical Trial Registry 12609000437268
- 2 March 2011
- Published by Springer Nature in Trials
- Vol. 12 (1) , 1-6
Open AccessAn intervention to promote physical activity and self-management in people with stable chronic heart failure The Home-Heart-Walk study: study protocol for a randomized controlled trial
Chronic heart failure (CHF) is a chronic debilitating condition with economic consequences, mostly because of frequent hospitalisations. Physical activity and adequate self-management capacity are important risk reduction strategies in the management of CHF. The Home-Heart-Walk is a self-monitoring intervention. This model of intervention has adapted the 6-minute walk test as a home-based activity that is self-administered and can be used for monitoring physical functional capacity in people with CHF. The aim of the Home-Heart-Walk program is to promote adherence to physical activity recommendations and improving self-management in people with CHF. A randomised controlled trial is being conducted in English speaking people with CHF in four hospitals in Sydney, Australia. Individuals diagnosed with CHF, in New York Heart Association Functional Class II or III, with a previous admission to hospital for CHF are eligible to participate. Based on a previous CHF study and a loss to follow-up of 10%, 166 participants are required to be able to detect a 12-point difference in the study primary endpoint (SF-36 physical function domain). All enrolled participant receive an information session with a cardiovascular nurse. This information session covers key self-management components of CHF: daily weight; diet (salt reduction); medication adherence; and physical activity. Participants are randomised to either intervention or control group through the study randomisation centre after baseline questionnaires and assessment are completed. For people in the intervention group, the research nurse also explains the weekly Home-Heart-Walk protocol. All participants receive monthly phone calls from a research coordinator for six months, and outcome measures are conducted at one, three and six months. The primary outcome of the trial is the physical functioning domain of quality of life, measured by the physical functioning subscale of the Medical Outcome Study Short Form -36. Secondary outcomes include physical functional capacity measured by the standard six minute walk test, self-management capacity, health related quality of life measured by Medical Outcome Study Short Form -36 and Minnesota Living With Heart Failure Questionnaire, self-efficacy and self-care behaviour. A self-monitoring intervention that can improve individual's exercise self-efficacy, self-management capacity could have potential significance in improving the management of people with chronic heart failure in community settings. Australian New Zealand Clinical Trial Registry 12609000437268